Kairos Pharma Receives Clinical Trials Arena Award for Prostate Cancer Treatment Development

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, has received the 2025 Clinical Trials Arena Excellence Award for Research and Development in Advanced Prostate Cancer. The award recognizes the company's progress with ENV-105 (carotuximab), a first-in-class CD105-targeting monoclonal antibody designed to overcome treatment resistance in metastatic castration-resistant prostate cancer.

The importance of this development lies in addressing a critical medical challenge in oncology. Metastatic castration-resistant prostate cancer represents an advanced stage of the disease where patients no longer respond to standard hormone therapies, creating significant unmet medical needs. Treatment resistance remains a major obstacle in cancer care, often leading to disease progression and limited options for patients.

ENV-105 targets CD105, a protein identified as a key driver of resistance to various cancer treatments. According to company information, elevation of CD105 in response to standard therapy results in resistance and disease relapse. The antibody aims to reverse drug resistance by targeting CD105 and restoring the effectiveness of standard therapies. This approach could potentially extend treatment options for patients who have developed resistance to existing therapies.

The award recognition follows positive interim safety and efficacy results from a Phase 2 randomized clinical trial evaluating ENV-105 in combination with apalutamide. The company is currently conducting this Phase 2 trial for castrate-resistant prostate cancer alongside a Phase 1 trial for lung cancer. These clinical developments represent important steps in validating the therapeutic approach across multiple cancer types.

For the biopharmaceutical industry, this recognition highlights the growing importance of addressing treatment resistance mechanisms in cancer therapeutics. The development of targeted approaches like ENV-105 represents a shift toward more precise interventions that could improve patient outcomes beyond current standard treatments. The company's focus on utilizing structural biology to overcome drug resistance and immune suppression in cancer reflects broader trends in oncology research.

Investors and stakeholders can access additional information through the company's newsroom at https://ibn.fm/KAPA. The broader context of this announcement includes the specialized communications platform InvestorWire, which provides distribution services for corporate communications. More details about their services are available at https://www.InvestorWire.com, with comprehensive terms and disclaimers accessible at https://www.InvestorWire.com/Disclaimer.

The implications of this award extend beyond corporate recognition to potential patient impact. If successful in clinical development, ENV-105 could provide a new therapeutic option for prostate cancer patients facing limited treatment alternatives. The approach of targeting resistance mechanisms rather than just cancer cells themselves represents an important evolution in cancer treatment strategies that could influence future drug development across oncology.